LivaNova (NSDQ:LIVN) announced today that it has agreed to sell its heart valve business to Gyrus Capital. London-based LivaNova’s board of directors unanimously approved the divestiture of the heart valve business in an effort to enable the company to “sharpen its focus” within its primary platforms, such as neuromodulation and cardiovascular, according to a news release. […]
LivaNova
Study: ECMO ‘significantly’ improves heart attack patients’ survival
The National Institutes of Health (NIH) is touting a study that found the use of life support improved survival in certain cardiac arrest patients. Published in The Lancet, the study, known as the Advanced Reperfusion Strategies for Refractory Cardiac Arrest (ARREST) trial, used the life support machine called extracorporeal membrane oxygenation ECMO to replicate the […]
LivaNova stock up on Street-beating Q3, CFO departing
LivaNova (NSDQ:LIVN) posted third-quarter results today that beat the consensus forecast on Wall Street, though the company still expects full-year sales between –7% and –17% on a constant-currency basis. LivaNova also announced that CFO Thad Huston will leave his position by Oct. 31 — after serving three and a half years with the company. Alex Shvartsburg, […]
LivaNova slides despite forecast-topping Q2 results
LivaNova (NSDQ:LIVN) shares dipped today despite second-quarter results that beat the consensus forecast. The London-based medtech company posted losses of -$88 million, or -$1.81 per share, on sales of $182.2 million for the three months ended June 30, 2020, for a massive bottom-line slide from losses of $29.2 million this time last year on a sales […]
LivaNova touts results of sutureless aortic valve study
LivaNova (NSDQ:LIVN) said today that its Perceval sutureless implant is safe and effective compared to standard aortic valve replacement, according to a clinical study. The study, presented at the 100th annual meeting of the American Association of Thoracic Surgery (AATS), revealed that the Perceval sutureless surgical aortic valve demonstrated freedom from major adverse cerebral and cardiovascular […]
LivaNova touts results of VNS treatment for bipolar depression
LivaNova (NSDQ:LIVN) today announced the publication of a new study that showed adding vagus nerve stimulation (VNS) therapy to treatment-as-usual significantly improves outcomes in patients with treatment-resistant bipolar depression (TRBD). Published in the International Journal of Bipolar Disorders, the study examined patients from a 5-year prospective registry and found 63% of 97 patients treated with VNS plus […]
LivaNova cardiopulmonary devices can be used longer under FDA coronavirus guidance
LivaNova (NSDQ:LIVN) announced that some of its cardiopulmonary products are now permitted for extended use in specific therapies after the FDA expanded device availability amid the COVID-19 pandemic. On April 6, the FDA issued guidance to temporarily expand the availability of certain devices in an effort to address the coronavirus crisis. Along the guidelines given by […]
LivaNova lands CE Mark for depression neurostimulation treatment
LivaNova (NSDQ:LIVN) said today that its vagus nerve stimulation therapy for treatment-resistant depression has won the CE Mark in Europe. Two patients in the United Kingdom were implanted with the company’s Symmetry system at the Musgrove Park Hospital in Taunton, England, making them the first patients to receive Symmetry devices outside the United States. The ability […]
Is Medtronic eyeing LivaNova for a takeover?
Some industry analysts are speculating that Medtronic (NYSE:MDT) might want to acquire LivaNova (NSDQ:LIVN) for its neuromodulation business. A source told financial intelligence company Reorg last week that someone pitched the idea to Medtronic, which would divest LivaNova’s cardiovascular business and “certain MDT cardiac surgery products.” “Five sector advisors said such a deal would make sense as […]
LivaNova adds Verily to depression study
LivaNova (NSDQ:LIVN) announced that it has added Google’s (NSDQ:GOOGL) Verily to its study of vagus nerve stimulation (VNS) therapy for difficult-to-treat depression (DTD). The Recover clinical will gather quantitative data on patient behavior using Verily’s technology and analytics. The data could help the researchers understand depressive episodes and the patient’s response to treatment. Study participants will […]
LivaNova pulls the plug on transcatheter mitral valve repair device
LivaNova (NSDQ:LIVN) said today that it is ending its Caisson Interventional transcatheter mitral valve replacement (TMVR) program and plans to restructure its heart valve business to improve profitability. The company’s heart valve business represented nearly $130 million in revenue during fiscal 2018 and saw its revenue numbers decline over the last five years, both with biological […]
